betrixaban and Cardiovascular-Diseases

betrixaban has been researched along with Cardiovascular-Diseases* in 1 studies

Trials

1 trial(s) available for betrixaban and Cardiovascular-Diseases

Article	Year
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association, 2017, Jul-11, Volume: 6, Issue:7 Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm.. Among hospitalized medically ill patients, extended-duration betrixaban demonstrated an ≈30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin. A total of 65 patients would require treatment with betrixaban to prevent 1 fatal or irreversible event versus enoxaparin.. URL: http://www.ClinicalTrials.gov. Unique identifier: NCT01583218. Topics: Acute Disease; Adult; Aged; Anticoagulants; Benzamides; Cardiovascular Diseases; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Inpatients; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Pyridines; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism	2017

Article

Year

Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.

Journal of the American Heart Association, 2017, Jul-11, Volume: 6, Issue:7

Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm.. Among hospitalized medically ill patients, extended-duration betrixaban demonstrated an ≈30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin. A total of 65 patients would require treatment with betrixaban to prevent 1 fatal or irreversible event versus enoxaparin.. URL: http://www.ClinicalTrials.gov. Unique identifier: NCT01583218.

Topics: Acute Disease; Adult; Aged; Anticoagulants; Benzamides; Cardiovascular Diseases; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Inpatients; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Pyridines; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism

2017